Compare CABA & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
| Metric | CABA | NEN |
|---|---|---|
| Founded | 2017 | 1977 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 227.9M |
| IPO Year | 2019 | N/A |
| Metric | CABA | NEN |
|---|---|---|
| Price | $2.31 | $63.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $14.57 | N/A |
| AVG Volume (30 Days) | ★ 4.2M | 1.1K |
| Earning Date | 11-10-2025 | 03-12-2026 |
| Dividend Yield | N/A | ★ 7.49% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.33 |
| Revenue | N/A | ★ $87,362,592.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $19.25 |
| Revenue Growth | N/A | ★ 7.63 |
| 52 Week Low | $0.99 | $62.10 |
| 52 Week High | $3.67 | $84.00 |
| Indicator | CABA | NEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 42.12 |
| Support Level | $2.42 | $63.10 |
| Resistance Level | $2.61 | $64.05 |
| Average True Range (ATR) | 0.25 | 0.69 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 20.38 | 38.01 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.